Prohost Biotech - Exclusive Biotech Research ~ A Comprehensive Resource for Biotech News

Gilead’s CAR T Product Yescarta Demonstrates Positive Survival Results

December 8, 2019 0

Gilead’s CAR-T Product Yescarta Results Kite, a Gilead (GILD) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. The data from the pivotal phase 2 study demonstrate that patients with refractory large B cell lymphoma were alive three years following a single infusion of Gilead’s CAR T …

Novartis to Acquire The Medicines Company at $85 a Share

Alnylam: Its Second RNAi Therapy Approval Boosted Savvy Investors’ Trust

Why Vertex and CRISPR Rallied Today

Another Approval for Celgene and the First for Acceleron

The Bad News That Might Save the Life of Halozyme...

The FDA Approves Compugen’s IND for Its Oncology Product COM902

When Negative Reactions to Biotechnology News Mislead. The Case of...

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and...

Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in...

Novartis: Plenty of Good News. See Also: Topics We Will...

More News for Nektar Therapeutics

Could Incyte’s Ruxolitinib Cream Effectively Treat Vitiligo?

Moderna Therapeutics: A Big Day Filled with Good News

Outperforming Biotechs In a Bad Market Day

Amgen to Acquire Celgene’s Product Otezla at $13.4 Billion

AstraZeneca and Vertex Both Have Good News

Why Akari Therapeutics Stock Price Rallied Today

Why Amgen’s Stock Is Up Over $11 Today

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News...

Today’s Highlights

Nektar at the 61st American Society of Hematology (ASH) Meeting

December 11, 2019 0

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at …

About the Prohost Portfolio Tables

December 5, 2019 0

Firstly, Forty-Seven and IVERIC bio We remind that the two condemned stocks Forty-Seven (FTSV) and IVERIC bio …

Let the Market Plummet But Not Our stocks

December 3, 2019 0

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, …

PTC Therapeutics’ Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

November 14, 2019 0

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics (PTCT) has positive results from part 2 of …

Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

November 13, 2019 0

Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints Reata Pharmaceuticals (RETA) announced that the …

Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

November 12, 2019 0

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis (EXEL) we learned that its …

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

November 8, 2019 0

Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis (EXEL) and Daiichi Sankyo …

Karyopharm Therapeutics: Is a Star Born?

November 6, 2019 0

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm …

IVERIC bio Stock Doubled and Continues to Outperform

November 1, 2019 0

IVERIC bio Stock Outperforms IVERIC bio (ISEE) has good news its stock is responding to. A …

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

October 21, 2019 0

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics (SGEN) announced positive topline results from …

The Week in Review

What A Week For Biotechnology

November 11, 2019 0

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …

The Quarterly Financial Results

November 4, 2019 0

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and …

What Was Seen and What Was Ignored

October 29, 2019 0

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History …

This Past Week

October 22, 2019 0

The Week in Review #43 This Past Week After hearing hints about the trade war between …

During the Departed Week

October 7, 2019 0

The Week in Review #42 During the Departed Week The week started with the market losing …

The Bizarre Market

August 20, 2019 0

The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started …

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Prohost Letters

An All Time High Market

November 23, 2019 0

Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets …

What Are We Experiencing Now?

October 4, 2019 0

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing …

The Value of the Biotech Companies Continued

September 23, 2019 0

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A …

The Value of the Biotech Companies

August 12, 2019 0

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and …

Treating Hemoglobinopathies

June 21, 2019 0

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell …

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …